Developing Therapeutically Enhanced Extracellular Vesicles for Atherosclerosis Therapy

atherosclerotic mice at a miR-145 dose 5000x less than synthetic nanoparticles. Collectively, it is demonstrated that genetic engineering of VSMCs with miR-145 produces therapeutically boosted EVs that reduce atherosclerosis plaque burden.